0000000000067943

AUTHOR

David B. Herzog

0000-0001-6406-7990

showing 12 related works from this author

Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with Major Depressive Disorder: Systemati…

2017

Early improvement of depressive symptoms during the first two weeks of antidepressant treatment has been discussed to be a resilience signal predicting a later positive treatment outcome in patients with Major Depressive Disorder (MDD). However, the predictive value of early improvement varies between studies, and the use of different antidepressants may explain heterogeneous results. The objective of this review was to assess the predictive value of early improvement on later response and remission and to identify antidepressants with the highest chance of early improvement. We included 17 randomized controlled trials investigating early improvement in 14,779 adult patients with MDD compar…

medicine.medical_specialtymedicine.drug_classmedia_common.quotation_subjectMirtazapineTricyclic antidepressantPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineOutcome Assessment Health CaremedicineHumansPsychiatryBiological Psychiatrymedia_commonDepressive Disorder MajorResilience Psychologicalmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthMeta-analysisAntidepressantMajor depressive disorderPsychological resiliencePsychology030217 neurology & neurosurgerymedicine.drugJournal of psychiatric research
researchProduct

Early life adversity targets the transcriptional signature of hippocampal NG2+ glia and affects voltage gated sodium (Nav) channels properties

2021

The precise mechanisms underlying the detrimental effects of early life adversity (ELA) on adult mental health remain still elusive. To date, most studies have exclusively targeted neuronal populations and not considered neuron-glia crosstalk as a crucially important element for the integrity of stress-related brain function. Here, we have investigated the impact of ELA, in the form of a limited bedding and nesting material (LBN) paradigm, on a glial subpopulation with unique properties in brain homeostasis, the NG2+ cells. First, we have established a link between maternal behavior, activation of the offspring's stress response and heterogeneity in the outcome to LBN manipulation. We furth…

Neurophysiology and neuropsychologyCandidate geneNav-channelsPhysiologyNa-channelsNeurosciences. Biological psychiatry. NeuropsychiatryHippocampal formationBiologyBiochemistryNG2+ gliaTranscriptome03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineEndocrinologyMediatorDownregulation and upregulationOriginal Research ArticleRC346-429Molecular BiologyVoltage-gated ion channelEndocrine and Autonomic SystemsQP351-495Nav-channels ; Scn7a ; Transcriptome ; Early life stress ; Translational psychiatry ; NG2+ gliaEarly life stress030227 psychiatryScn7aCrosstalk (biology)nervous systemNeurology. Diseases of the nervous systemTranscriptomeNeuroscienceTranslational psychiatry030217 neurology & neurosurgeryHomeostasisRC321-571Neurobiology of Stress
researchProduct

Early onset of depression and treatment outcome in patients with major depressive disorder

2021

Major depressive disorder (MDD) is a highly heterogeneous disorder, which may partly explain why treatment outcome using antidepressants is unsatisfactory. We investigated the onset of depression as a possible clinical marker for therapy response prediction in the context of somatic biomarkers blood pressure and plasma electrolyte concentration. 889 MDD patients were divided into early (EO, n = 226), intermediate (IO, n = 493), and late onset (LO, n = 169) patients and were analyzed for differences in socio-demographic and clinical parameters, comorbidities and treatment outcome as well as systolic blood pressure and electrolytes. EO patients more often suffered from a recurrent depression,…

medicine.medical_specialtyTreatment outcomeLate onsetContext (language use)03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineIn patientAge of OnsetBiological PsychiatryDepression (differential diagnoses)Early onsetDepressive Disorder MajorDepressionbusiness.industrymedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTreatment OutcomeBlood pressureMajor depressive disorderbusiness030217 neurology & neurosurgeryJournal of Psychiatric Research
researchProduct

Paroxetine Administration Affects Microbiota and Bile Acid Levels in Mice.

2020

Recent interest in the role of microbiota in health and disease has implicated gut microbiota dysbiosis in psychiatric disorders including major depressive disorder. Several antidepressant drugs that belong to the class of selective serotonin reuptake inhibitors have been found to display antimicrobial activities. In fact, one of the first antidepressants discovered serendipitously in the 1950s, the monoamine-oxidase inhibitor Iproniazid, was a drug used for the treatment of tuberculosis. In the current study we chronically treated DBA/2J mice for 2 weeks with paroxetine, a selective serotonin reuptake inhibitor, and collected fecal pellets as a proxy for the gut microbiota from the animals…

medicine.drug_classlcsh:RC435-571Serotonin reuptake inhibitorClinical SciencesmicrobiomeGut floraPharmacology03 medical and health sciences0302 clinical medicineRare Diseaseslcsh:PsychiatrymedicinePsychologyMicrobiomeCancerOriginal ResearchPsychiatrybile acidsantidepressantbiologyBile acidbusiness.industryDepressionbiology.organism_classificationmedicine.diseaseParoxetinemetabolomics030227 psychiatryColo-Rectal CancerPsychiatry and Mental healthMental HealthGood Health and Well Being5.1 PharmaceuticalsPublic Health and Health ServicesAntidepressantDevelopment of treatments and therapeutic interventionsbusinessDigestive DiseasesDysbiosis030217 neurology & neurosurgeryBehavioural despair testmedicine.drugparoxetineFrontiers in psychiatry
researchProduct

Bioenergetic shift and actin cytoskeleton remodelling as acute vascular adaptive mechanisms to angiotensin II in murine retina and ophthalmic artery

2020

Ocular vascular dysfunction is a major contributing factor to the pathogenesis of glaucoma. In recent years, there has been a renewed interest in the role of angiotensin II (Ang II) in mediating the disease progression. Despite its (patho)physiological importance, the molecular mechanisms underlying Ang II-mediated oxidative stress remain largely unexplored in the ocular vasculature. Here, we provide the first direct evidence of the alterations of proteome and signalling pathways underlying Ang II-elicited oxidative insult independent of arterial pressure changes in the ophthalmic artery (OA) and retina (R) employing an in vitro experimental model. Both R and OA were isolated from male C57B…

0301 basic medicineMaleClinical BiochemistryBiologyBioenergeticsProteomicsBiochemistryRetinaPathogenesis03 medical and health sciencesMice0302 clinical medicineArticles from the Special Issue on Oxidative stress in retina and retinal pigment epithelium in health and disease; Edited by Vera BonilhaDownregulation and upregulationOphthalmic arteryAnimalsCytoskeletonlcsh:QH301-705.5Cytoskeletonlcsh:R5-920KinaseAngiotensin IIOrganic ChemistryGlaucomaActin cytoskeletonAngiotensin IICell biologyMice Inbred C57BLActin Cytoskeleton030104 developmental biologylcsh:Biology (General)Proteomelcsh:Medicine (General)Oxidation-Reduction030217 neurology & neurosurgeryRedox Biology
researchProduct

Effects of age on depressive symptomatology and response to antidepressant treatment in patients with major depressive disorder aged 18 to 65 years

2020

Background: There is evidence that symptomatology in patients with major depressive disorder (MDD) changes with age. However, studies comparing depressive symptomatology between different age groups during antidepressant therapy are rare. We compared demographic and clinical characteristics in depressed patients of different age groups at baseline and during treatment. Methods: 889 MDD inpatients were divided into four age groups (18–29, 30–39, 40–49, 50–65 yrs.). Demographic and clinical characteristics including depressive symptomatology (assessed by the Inventory of Depressive Symptoms) were assessed at baseline and weekly during treatment. Results: At baseline, young patients (18–29 yea…

AdultMalePediatricsmedicine.medical_specialtyAdolescentlcsh:RC435-571IrritabilityDepressive symptomatology03 medical and health sciencesYoung Adult0302 clinical medicinelcsh:PsychiatrymedicineHumansIn patientDepression (differential diagnoses)AgedDepressive Disorder Majorbusiness.industryDepressionAge FactorsMiddle Agedmedicine.diseasePersonality disordersAntidepressive AgentsIrritable MoodSelf Concept030227 psychiatrySubstance abusePsychiatry and Mental healthClinical PsychologyTreatment OutcomeAntidepressantMajor depressive disorderFemalemedicine.symptombusiness030217 neurology & neurosurgeryComprehensive Psychiatry
researchProduct

Sexually Dimorphic Behavioral Profile in a Transgenic Model Enabling Targeted Recombination in Active Neurons in Response to Ketamine and (2R,6R)-Hyd…

2020

Background: Rapid-acting antidepressants ketamine and (2R,6R)-hydroxynorketamine ((2R,6R)-HNK) have overcome some of the major limitations of classical antidepressants. However, little is known about sex-specific differences in the behavioral and molecular effects of ketamine and (2R,6R)-HNK in rodents. Methods: We treated mice with an intraperitoneal injection of either saline, ketamine (30 mg kg&minus

Male0301 basic medicineHydroxynorketaminemedicine.medical_treatmentAntidepressantAnxietyHippocampuslcsh:Chemistry0302 clinical medicinelcsh:QH301-705.5Salineactivated neuronsSpectroscopyNeuronsRecombination GeneticSex CharacteristicsBehavior AnimalhydroxynorketamineGeneral MedicineComputer Science ApplicationsActivated neuronsAntidepressantFemaleKetaminemedicine.drugmedicine.medical_specialtyketamineMemory Episodicsex differenceGreen Fluorescent ProteinsIntraperitoneal injectionMice TransgenicIn situ hybridizationBiologyHydroxynorketamineArticleCatalysisInorganic Chemistry03 medical and health sciencesInternal medicineketamine ; sex difference ; activated neurons ; antidepressant ; behavior ; BDNF ; rapid-acting ; hydroxynorketaminemedicineAnimalsKetamineRapid-actingPhysical and Theoretical ChemistrySocial BehaviorMolecular BiologyCell NucleusBehaviorantidepressantbehaviorBrain-Derived Neurotrophic FactorOrganic ChemistrySex differencerapid-actingSexual dimorphismDisease Models AnimalBDNF030104 developmental biologyEndocrinologylcsh:Biology (General)lcsh:QD1-999030217 neurology & neurosurgeryBehavioural despair test
researchProduct

Longitudinal CSF proteome profiling in mice to uncover the acute and sustained mechanisms of action of rapid acting antidepressant (2R,6R)-hydroxynor…

2021

Delayed onset of antidepressant action is a shortcoming in depression treatment. Ketamine and its metabolite (2R,6R)-hydroxynorketamine (HNK) have emerged as promising rapid-acting antidepressants. However, their mechanism of action remains unknown. In this study, we first described the anxious and depression-prone inbred mouse strain, DBA/2J, as an animal model to assess the antidepressant-like effects of ketamine and HNK in vivo. To decode the molecular mechanisms mediating HNK's rapid antidepressant effects, a longitudinal cerebrospinal fluid (CSF) proteome profiling of its acute and sustained effects was conducted using an unbiased, hypothesis-free mass spectrometry-based proteomics app…

ProteomicsNeurophysiology and neuropsychologyanimal structuresHydroxynorketaminePhysiologyGlucocorticoid receptor signalingAntidepressantCSFNeurosciences. Biological psychiatry. NeuropsychiatryBiologyPharmacologyProteomicsBiochemistryCellular and Molecular NeuroscienceEndocrinologyGlucocorticoid receptorNeurotrophic factorsmedicineOriginal Research ArticleKetamine ; CSF ; Antidepressant ; (2R6R)-Hydroxynorketamine ; Glucocorticoid receptor signaling ; ProteomicsRC346-429Molecular BiologyPI3K/AKT/mTOR pathwayEndocrine and Autonomic SystemsQP351-495Mechanism of action(2R6R)-Hydroxynorketamineembryonic structuresAntidepressantKetamineNeurology. Diseases of the nervous systemmedicine.symptomSignal transductionRC321-571Neurobiology of Stress
researchProduct

Decoding the Mechanism of Action of Rapid-Acting Antidepressant Treatment Strategies: Does Gender Matter?

2019

Gender differences play a pivotal role in the pathophysiology and treatment of major depressive disorder. This is strongly supported by a mean 2:1 female-male ratio of depression consistently observed throughout studies in developed nations. Considering the urgent need to tailor individualized treatment strategies to fight depression more efficiently, a more precise understanding of gender-specific aspects in the pathophysiology and treatment of depressive disorders is fundamental. However, current treatment guidelines almost entirely neglect gender as a potentially relevant factor. Similarly, the vast majority of animal experiments analysing antidepressant treatment in rodent models exclus…

MalePsychotherapistsex differencemedia_common.quotation_subjectmedicine.medical_treatmentReviewelectroconvulsive therapyCatalysisNeglectlcsh:ChemistryInorganic Chemistryendocrinology03 medical and health sciences0302 clinical medicineElectroconvulsive therapygendermedicineAnimalsHumansPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopyDepression (differential diagnoses)media_commonDepressive Disorder Majorantidepressantbusiness.industryOrganic ChemistryGeneral MedicineRapid-acting antidepressantrapid-actingmedicine.diseaseAntidepressive Agents030227 psychiatryComputer Science ApplicationsReview articleTreatment Outcomelcsh:Biology (General)lcsh:QD1-999(2R6R)-HydroxynorketaminedepressionTreatment strategyAntidepressantMajor depressive disorderFemaleKetaminebusiness030217 neurology & neurosurgery
researchProduct

Rapid acting antidepressant (2R,6R)-hydroxynorketamine (HNK) targets glucocorticoid receptor signaling: a longitudinal cerebrospinal fluid proteome s…

2020

AbstractDelayed onset of antidepressant action is a shortcoming in depression treatment. Ketamine and its metabolite (2R,6R)-hydroxynorketamine (HNK) have emerged as promising rapidacting antidepressants. However, their mechanism of action remains unknown. In this study, we first described the anxious and depression-prone inbred mouse strain, DBA/2J, as a animal model to assess the antidepressant-like effects of ketamine and HNK in vivo. To decode the molecular mechanisms mediating HNK’s rapid antidepressant effects, a longitudinal cerebrospinal fluid (CSF) proteome profiling of its acute and sustained effects was conducted using an unbiased, hypothesis-free mass spectrometry-based proteomi…

Glucocorticoid receptorHydroxynorketamineMechanism of actionNeurotrophic factorsProteomemedicineSignal transductionPharmacologyBiologymedicine.symptomProteomicsPI3K/AKT/mTOR pathway
researchProduct

Early life stress programming of NG2+ glia transcriptome alters functional properties of voltage gated sodium (Nav) channels and cognitive performance

2020

AbstractThe precise mechanisms underlying the detrimental effects of early life stress (ELS) on adult mental health remain still elusive. To date, most studies have exclusively targeted neuronal populations and not considered neuron-glia crosstalk as a crucially important element for the integrity of stress-related brain function. Here, we have investigated the impact of ELS on a glial subpopulation with unique properties in brain homeostasis, the NG2+ cells. ELS shifted the NG2+ transcriptome towards more mature stages, and these transcriptional effects were dependent on stress-induced glucocorticoids. The functional relevance of one candidate gene, Scn7a, could be confirmed by an increase…

TranscriptomeCrosstalk (biology)Candidate genenervous systemVoltage-gated ion channelDownregulation and upregulationEffects of sleep deprivation on cognitive performanceBiologyHippocampal formationNeuroscienceHomeostasis
researchProduct

Common genes associated with antidepressant response in mouse and man identify key role of glucocorticoid receptor sensitivity.

2017

Response to antidepressant treatment in major depressive disorder (MDD) cannot be predicted currently, leading to uncertainty in medication selection, increasing costs, and prolonged suffering for many patients. Despite tremendous efforts in identifying response-associated genes in large genome-wide association studies, the results have been fairly modest, underlining the need to establish conceptually novel strategies. For the identification of transcriptome signatures that can distinguish between treatment responders and nonresponders, we herein submit a novel animal experimental approach focusing on extreme phenotypes. We utilized the large variance in response to antidepressant treatmen…

0301 basic medicineMicroarraysPhysiologyGene ExpressionBioinformaticsBiochemistryBiomarkers PharmacologicalTranscriptomeMice0302 clinical medicineGlucocorticoid receptorMedicine and Health SciencesBiology (General)DepressionGeneral NeuroscienceBrainDrugsAntidepressantsPhenotypeAntidepressive Agents3. Good healthBody FluidsParoxetineBioassays and Physiological AnalysisBloodMice Inbred DBAMultigene FamilyMajor depressive disorderAntidepressantDNA microarrayAnatomyGeneral Agricultural and Biological SciencesResearch ArticleQH301-705.5Antidepressant drug therapy ; Blood ; Gene regulation ; Biomarkers ; Depression ; Gene expression ; Microarrays ; AntidepressantsBiologyResearch and Analysis MethodsGeneral Biochemistry Genetics and Molecular BiologyBlood Plasma03 medical and health sciencesReceptors GlucocorticoidMental Health and PsychiatrymedicineGeneticsAnimalsHumansGene RegulationPharmacologyDepressive Disorder MajorGeneral Immunology and MicrobiologyMechanism (biology)Mood DisordersGene Expression ProfilingBiology and Life Sciencesmedicine.diseaseGene expression profiling030104 developmental biologyGene Expression RegulationCorticosterone030217 neurology & neurosurgeryBiomarkersPLoS biology
researchProduct